Puma Biotechnology (PBYI) Receives a Buy from H.C. Wainwright
In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Puma Biotechnology (PBYI), with a price target of $15.00. The company’s shares closed last Friday at $10.84.
According to TipRanks.com, White is a top 100 analyst with an average return of 55.1% and a 62.1% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics.
Puma Biotechnology has an analyst consensus of Moderate Buy, with a price target consensus of $11.00.
See today’s analyst top recommended stocks >>
Puma Biotechnology’s market cap is currently $437.4M and has a P/E ratio of -7.60. The company has a Price to Book ratio of -5.60.
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PBYI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.